What you need to know:
– Phillips, global healthcare technology leader, has announced the release of Truncend Plus, the next generation of EPIQ CVX and Affiniti CVX cardiovascular ultrasound systems.
– The new system features major advances in image quality and artificial intelligence (AI), including new FDA-cleared 2D and 3D image quality enhancements and an expanded suite of AI-enabled clinical applications. Trunscend Plus is designed to help heart disease teams work smarter and smarter to address growing challenges such as increasing patient volume, increased clinical complexity, and understaffing.
AI-equipped cardiovascular ultrasound system
The latest FDA-cleared extensions for EPIQ CVX and Affiniti CVX systems provide visibly improved sharpness, contrast and detail for 2D and 3D imaging. These upgrades support excellent visualization of cardiac anatomy and function. This can help improve your diagnosis confidence even in complex situations. The system also introduces the new 2D Auto EF Advanced Feature, which is essential for accurately assessing cardiac function, extending the AI capabilities of contrast images.
Philips currently offers 26 FDA Claired Cardiovascular Ultrasound AI Applications. This is the most common in the industry. These applications are fully integrated into Truncend Plus for both EPIQ and Affiniti CVX systems. Among the latest extensions that receive FDA clearance are 2D Auto EF and 2D Auto EF Advanced. These tools are designed to streamline clinical workflows and improve diagnostic accuracy across a variety of care settings.
“Artificial intelligence is not a threat, but a tool, and I've always argued that humans and AI are superior to humans or AI alone. 3D automatic CFQ and 3D auto-TV AI applications take manual, time-consuming processes and automate these measurements in a fast, simple, and reproducible way. Cardiology at Feinberg School of Medicine, Northwestern University and Bloom Cardiovascular Research Institute.
A key application of cardiac imaging is left ventricular (LV) function assessment. Trunscend Plus supports this need by providing fast, reproducible results that help cardiologists quickly and consistently assess LV function across different patients. Automated tools minimize operator variability and ensure more reliable, standardized measurements.
The Philips Ultrasound System is estimated to carry out 1.333 billion diagnostic and intervention procedures each year, supporting the diagnosis and treatment of 654 million unique patients annually.
